스위스 - 독일어 - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - toxoidum diphtheriae, toxoidum tetani, toxoidum pertussis, haemagglutininum filamentosum (b. pertussis), pertactinum (b. pertussis), virus poliomyelitis typus 1 inactivatus (stamm mahoney), virus poliomyelitis typus 2 inactivatus (stamm mef-1), virus poliomyelitis typus 3 inactivatus (stamm saukett), hepatitidis b viri antigenum adnr, polysaccharida haemophili influenzae typus b 20752 conjugata cum toxoido tetani - pulver und suspension zur herstellung einer injektionssuspension - i) dtpa-hepb-ipv: toxoidum diphtheriae min. 30 u.i., toxoidum tetani min. 40 u.i., toxoidum pertussis 25 µg, haemagglutininum filamentosum (b. pertussis) 25 µg, pertactinum (b. pertussis) 8 µg, virus poliomyelitis typus 1 inactivatus (stamm mahoney) 40 u.i., virus poliomyelitis typus 2 inactivatus (stamm mef-1) 8 u.i., virus poliomyelitis typus 3 inactivatus (stamm saukett) 32 u.i., hepatitidis b viri antigenum adnr 10 µg, aluminium 0.5 mg ut aluminii hydroxidum hydricum ad adsorptionem, aluminium 0.2 mg ut aluminii phosphas, natrii chloridum corresp. natrium 1.8 mg, medium 199, aqua ad iniectabile ad suspensionem pro 0.5 ml, residui: neomycini sulfas, polymyxini b sulfas, formaldehydum, polysorbatum 20, polysorbatum 80. ii) hib: polysaccharida haemophili influenzae typus b 20752 conjugata cum toxoido tetani 10 µg, lactosum, aluminium 0.12 mg ut aluminii phosphas, pro praeparatione. i) et ii) corresp. dtpa-hepb-ipv + hib: toxoidum diphtheriae min. 30 u.i., toxoidum tetani min. 40 u.i., toxoidum pertussis 25 µg, haemagglutininum filamentosum (b. pertussis) 25 µg, pertactinum (b. pertussis) 8 µg, virus poliomyelitis typus 1 inactivatus (stamm mahoney) 40 u.i., virus poliomyelitis typus 2 inactivatus (stamm mef-1) 8 u.i., virus poliomyelitis typus 3 inactivatus (stamm saukett) 32 u.i., hepatitidis b viri antigenum adnr 10 µg, polysaccharida haemophili influenzae typus b 20752 conjugata cum toxoido tetani 10 µg, aluminium 0.5 mg ut aluminii hydroxidum hydricum ad adsorptionem, aluminium 0.32 mg ut aluminii phosphas, natrii chloridum corresp. natrium 1.8 mg, medium 199, lactosum, aqua ad iniectabile ad suspensionem pro 0.5 ml, residui: neomycini sulfas, polymyxini b sulfas, formaldehydum, polysorbatum 20, polysorbatum 80. - grundimmunisierung und auffrischimpfung, gegen diphtherie, tetanus, pertussis, hepatitis b, poliomyelitis und haemophilus influenzae typ b, ab der vollendeten 6. lebenswoche - impfstoffe

스위스 - 독일어 - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - proteinum l1 papillomaviri des menschlichen typ 16, proteinum l1 papillomaviri menschlichen typ 18 - suspension zur i.m. injektion - proteinum l1 papillomaviri humani typus 16 20 µg, proteinum l1 papillomaviri humani typus 18 20 µg, adeps a 3-o-desacyl-4’-monophosphorylatus, aluminium ut aluminii hydroxidum hydricum ad adsorptionem, natrii chloridum, natrii dihydrogenophosphas dihydricus, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.82 mg. - aktive immunisierung gegen gebärmutterhalskrebs, ab dem 10. geburtstag - impfstoffe

스위스 - 독일어 - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - suspension zur i.m. injektion

스위스 - 독일어 - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - injektionssuspension

스위스 - 독일어 - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - injektionssuspension

스위스 - 독일어 - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - injektionssuspension

스위스 - 독일어 - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - hepatitis-a-virus inactivatus - injektionssuspension - impfstoff adsorbatum: hepatitis-a-virus inactivatus 1440 u., proteina, aluminium, aluminii hydroxidum hydricum zu adsorptionem, aminoacida, polysorbatum 20, dinatrii phosphas, kalii phosphates oder, natrii chloridum, kalii chloridum, der rest: neomycini sulfas max. 20 ng, wasser q.s. um die suspension für 1 ml. - aktive immunisierung gegen hepatitis a, ab dem vollendeten 18. lebensjahr - impfstoffe

스위스 - 독일어 - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - hepatitis-a-virus inactivatus - injektionssuspension - impfstoff adsorbatum: hepatitis-a-virus inactivatus 720 u., aluminium, aluminii hydroxidum hydricum zu adsorptionem, aminoacida, polysorbatum 20, dinatrii phosphas, kalii phosphates oder, natrii chloridum, kalii chloridum, der rest: proteina max. 0,2 µg, neomycini sulfas, wasser q.s. zu der suspension 0,5 ml. - aktive immunisierung gegen hepatitis a, ab dem vollendeten 1. bis zum vollendeten 18. lebensjahr - impfstoffe